Scientists develop a sensor for the most important human cancer gene

November 14, 2017, Dresden University of Technology
Model of the TP53 sensor. The Sensor is symbolized as a 'thermometer' that displays the TP53 status in the cell. Credit: TU Dresden, Frank Buchholz

If it burns in a house smoke detectors alert us hence protecting life. A molecular smoke alert has now been developed by Dresden researchers for the TP53 gene, the most important human cancer gene. The alert goes on if the TP53 gene is mutated in cells. The molecular smoke detector works like a TP53 sensor, which monitors the correct function of the gene. A non-functional TP53 gene is going to activate the sensor, which initiates cell death. Results from this study from the research team of Prof. Frank Buchholz are now published in the journal Nature Communications.

Cancer is caused by changes in the human genome. Mutations in oncogenes and in accumulate unrecognized over time and lead to uncontrolled cell proliferation eventually. In 50% of all human tumors the tumor suppressor gene TP53 is no longer functional being the most frequently mutated gene. TU Dresden-Scientists from the University Cancer Center UCC at the University Hospital Carl Gustav Carus, the National Center for Tumor Diseases NCT Dresden and the German Cancer Consortium DKTK Dresden concluded that the formation of a TP53 sensor could suppress tumor formation at a very early stage.

To achieve this they designed a genetic element that makes cell function dependent on normal TP53. If the TP53 function is interrupted, the sensor gets activated and initiates cell death. "We treat cancer long after they have gone through the transformation process," says Prof. Dr. med. Frank Buchholz describing the current situation. As a result, therapy is often too late to be able to eliminate all cancer cells in the body. Furthermore, due to additional mutations, therapy-resistant clones quickly emerge from some .

"The TP53 sensor enables an active precocious intervention for the first time. Our results show that cells with TP53 mutations can be selectively detected and eliminated at an early stage. Hence, the transformation process is prevented." The researchers plan to use their initial findings to develop new cancer diagnostics and to establish a protection system against cancer mutations in the long-term.

Explore further: New insights into potent cancer tumour suppressor gene

More information: Jovan Mircetic et al, Development of a genetic sensor that eliminates p53 deficient cells, Nature Communications (2017). DOI: 10.1038/s41467-017-01688-w

Related Stories

New insights into potent cancer tumour suppressor gene

September 22, 2016
New insight into the function of a gene important in the suppression of cancer is published today. Researchers at the National University of Ireland Galway have shown that the TP53 gene has even greater anti-cancer activity ...

Mutations unveiled that predispose lung cancers to refractory histologic transformation

June 7, 2017
Cancer pedigree analysis reveals the mutations in RB1 and TP53 genes play a key role in treatment-resistant, cancer cell-type transformation during EGFR inhibitor therapy for lung cancers.

Specific gene in the tumor determines the effectiveness of cancer treatment

April 14, 2016
A cancer treatment can be basically effective but, equally, it may have negative consequences. Hitherto, it has not been possible to determine prior to treatment whether a patient will benefit from standard cancer treatment ...

Germline TP53 mutations in patients with early-onset colorectal cancer

March 12, 2015
In a group of patients diagnosed with colorectal cancer at 40 or younger, 1.3 percent of the patients carried germline TP53 gene mutations, although none of the patients met the clinical criteria for an inherited cancer syndrome ...

Yin and yang: Immune signaling protein has opposing roles in breast cancer development

June 8, 2015
Countering previously held beliefs, researchers at the University of Texas MD Anderson Cancer Center have discovered that inhibiting the immune receptor protein TLR4 may not be a wise treatment strategy in all cancers. This ...

New therapeutic approach for difficult-to-treat subtype of ovarian cancer identified

July 24, 2017
A potential new therapeutic strategy for a difficult-to-treat form of ovarian cancer has been discovered by Wistar scientists. The findings were published online in Nature Cell Biology.

Recommended for you

New drug seeks receptors in sarcoma cells, attacks tumors in animal trials

December 13, 2018
A new compound that targets a receptor within sarcoma cancer cells shrank tumors and hampered their ability to spread in mice and pigs, a study from researchers at the University of Illinois reports.

Surgery unnecessary for many prostate cancer patients

December 13, 2018
Otherwise healthy men with advanced prostate cancer may benefit greatly from surgery, but many with this diagnosis have no need for it. These conclusions were reached by researchers after following a large group of Scandinavian ...

Combining three treatment strategies may significantly improve melanoma treatment

December 12, 2018
A study by a team led by a Massachusetts General Hospital (MGH) investigator finds evidence that combining three advanced treatment strategies for malignant melanoma—molecular targeted therapy, immune checkpoint blockade ...

Lethal combination: Drug cocktail turns off the juice to cancer cells

December 12, 2018
A widely used diabetes medication combined with an antihypertensive drug specifically inhibits tumor growth—this was discovered by researchers from the University of Basel's Biozentrum two years ago. In a follow-up study, ...

Researchers use computer model to predict prostate cancer progression

December 12, 2018
An international team of cancer researchers from Denmark and Germany have used cancer patient data to develop a computer model that can predict the progression of prostate cancer. The model is currently being implemented ...

An integrated approach to finding new treatments for breast cancer

December 12, 2018
Unraveling the complexity of cancer biology can lead to the identification new molecules involved in breast cancer and prompt new avenues for drug development. And proteogenomics, an integrated, multipronged approach, seems ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.